ReviewCurrent opinion in rheumatology2020
Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
Review in Current opinion in rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Immunotherapy · 2025Pooled it
- Toward Precision Health in Autoimmunity and Immune-Related Adverse Events: The Autoantibody Reactome, Spatial Omics, and Multimodal Data Integration.Biomedicines · 2026Article
- Article
- The management of rheumatic immune related adverse events.Best practice & research. Clinical rheumatology · 2026Review
- Exploratory Clinical Study to Evaluate the Efficacy and Safety of Sulfasalazine for Immune Checkpoint Inhibitor (ICI)-Induced Colitis.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- miRNA in Diagnosis and Therapeutics of Tuberculosis: Importance in Latent and Brain Associated Pathologies.Current pharmaceutical design · 2026Review
- The TIM-3/Gal-9 Pathway: A Promising Therapeutic Target for Regulation of Immune Checkpoint in Rheumatoid Arthritis.Current rheumatology reviews · 2026Review
- Review
- Systematic review and meta-analysis on the effect of physical exercise on self-reported pain in patients with metastatic cancer.Journal of cancer survivorship : research and practice · 2025Review
- Blocking the IL‑6 pathway to treat immune checkpoint inhibitor‑induced inflammatory arthritis (Review).Molecular medicine reports · 2025Review
- Immune checkpoint inhibitors: From friend to foe.Toxicology reports · 2025Article
- Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy.Journal of clinical medicine · 2025Review
- Regulatory Role of IL6 in Immune-Related Adverse Events during Checkpoint Inhibitor Treatment in Melanoma.International journal of molecular sciences · 2024Article
- Dynamic Release from Acetalated Dextran Nanoparticles for Precision Therapy of Inflammation.ACS applied bio materials · 2024Article
- Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.Rheumatic diseases clinics of North America · 2024Review
- Histologically Proven Recurrent Synovitis after Nivolumab Treatment.Internal medicine (Tokyo, Japan) · 2024Article
- Rapid identification of inflammatory arthritis and associated adverse events following immune checkpoint therapy: a machine learning approach.Frontiers in immunology · 2024Article
- Clonally expanded CD38Science immunology · 2023Article
- Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis.Annals of the rheumatic diseases · 2023Observational
- The oncogenic role of tubulin alpha-1c chain in human tumours.BMC cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThis review summarizes the current evidence on treatment strategies for inflammatory arthritis because of cancer treatment with immune checkpoint inhibitors (ICI), prognosis of ICI-induced arthritis, and management of patients with preexisting inflammatory arthritis receiving ICI therapy. RECENT
findingsInflammatory arthritis is the most common rheumatic immune-related adverse event observed in patients receiving ICI therapy. Most patients can successfully be treated with low doses of corticosteroids or conventional synthetic disease modifying anti-rheumatic drugs (DMARDs). A small minority will develop severe symptoms requiring biologic therapy including TNF inhibitors and IL-6 receptor inhibitors. Many cases of inflammatory arthritis will resolve with cessation of ICI therapy. Some patients will develop persistent arthritis despite discontinuation. Patients with preexisting inflammatory arthritis (e.g. rheumatoid arthritis) commonly flare on ICI therapy, but can usually be managed with corticosteroids. SUMMARY: Inflammatory arthritis following ICI therapy for cancer is relatively common and the practicing rheumatologist should be able to recognize and manage it in conjunction with Oncology. The majority of patients respond to corticosteroids, but some will need treatment with conventional synthetic or biologic DMARDs. Additional studies should investigate the effects of immunosuppression on tumor response and the use of ICI therapy in patients with preexisting autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.